Actively Recruiting
Active Surveillance for Low Risk Prostate Cancer
Led by I.M. Sechenov First Moscow State Medical University · Updated on 2021-07-22
100
Participants Needed
1
Research Sites
365 weeks
Total Duration
On this page
Sponsors
I
I.M. Sechenov First Moscow State Medical University
Lead Sponsor
M
Moscow Regional Research and Clinical Institute (MONIKI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
An active surveillance protocol for patients diagnosed low-risk prostate cancer will be held. We plan to use PSA (prostate-specific antigen) testing, DRE (digital rectal examination), TRUS (transrectal ultrasound), MRI (magnetic resonance imaging) and follow-up biopsies to monitor patients and detect cancer progression in time.
CONDITIONS
Official Title
Active Surveillance for Low Risk Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Prostate adenocarcinoma confirmed by at least 12 core biopsy
- Patient understands the study and agrees to participate by signing consent
- Low oncological risk as per EAU Guidelines: stage T1-T2a, PSA less than 10 ng/ml, ISUP score 1 (Gleason score 3+3=6)
- No more than 33% of biopsy cores contain adenocarcinoma
You will not qualify if you...
- Previous treatment for prostate cancer
- Other malignant prostate tumors
- Other cancer diseases
- Treatment with 5-alpha-reductase inhibitors
- Patient refuses to continue in the study
- Patient wants to begin treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institute for Urology and Reproductive Health, Sechenov University.
Moscow, Russia, 119991
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here